Inactive Instrument

Press Releases AbbVie Euronext Paris

Equities

ABBV

US00287Y1091

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383	09:01am	PR
RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis	Jun. 04	PR
Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50	Jun. 04	PR
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	Jun. 04	AQ
AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference	Jun. 03	PR
AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis	May. 31	PR
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results	May. 29	AQ
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation	May. 21	AQ
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week	May. 20	AQ
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders	May. 13	PR
QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults	May. 08	AQ
AbbVie to Present at the Bank of America Securities Healthcare Conference	May. 06	PR
AbbVie : Reinforces Commitment to Science and Innovation with a €150 million Euro Investment in New Cutting-Edge Research and Development Facility in Germany	Apr. 30	PU
AbbVie: Q1 Earnings Snapshot	Apr. 26	AQ
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study	Apr. 25	PR
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX Cosmetic and Their Other Biggest Brands	Apr. 24	AQ
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands	Apr. 23	PR
AbbVie - Phase 3 SELECT-GCA Study of Upadacitinib showed Positive Results in Patients with Giant Cell Arteritis	Apr. 19	AQ
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis	Apr. 18	PR
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant for Preventive Treatment of Migraine	Apr. 15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases AbbVie Euronext Paris

Equities

ABBV

US00287Y1091

Press Releases

Filters